Myozyme

Myozyme Caution For Usage

Manufacturer:

Genzyme
/
Sanofi-Aventis

Distributor:

DKSH
Full Prescribing Info
Caution For Usage
Special Precautions for Disposal and Other Handling: Myozyme has to be reconstituted with water for injections then diluted with sodium chloride 9 mg/mL (0.9%) solution and then administered by IV infusion. Reconstitution and dilution should be performed in accordance with good practice rules, particularly for the respect of asepsis.
Due to the proteinaceous nature of the product, particle formation may occur in the reconstituted solution and final infusion bags. Therefore, 0.2 micron low protein-binding in-line filter should be used for administration. It was demonstrated that the use of a 0.2 micron in-line filter removes visible particles and does not result in an apparent loss of protein or activity.
Determine the number of vials to be reconstituted based on the individual patient's dose regimen (mg/kg) and remove the required vials from the refrigerator in order to allow them to reach room temperature (approximately 30 mins). As Myozyme does not contain a preservative, each vial of Myozyme is for single use only.
Use Aseptic Technique: Reconstitution: Reconstitute each 50 mg vial of Myozyme with 10.3 mL water for injections. Add the water for injections by slow drop-wise addition down the side of the vial and not directly onto the lyophilized cake. Tilt and roll each vial gently. Do not invert, swirl or shake the vial The reconstituted volume is 10.5 mL containing 5 mg/mL, and appears as a clear, colourless to pale yellow solution which may contain particles in the form of thin white strands or translucent fibres. Perform an immediate inspection of the reconstituted vials for particulate matter and discoloration. If upon immediate inspection foreign particles other than those described previously are observed, or if the solution is discoloured, do not use. The pH of the reconsituted solution approximately 6.2.
After reconstitution, it is recommended to promptly dilute the vials.
Dilution: When reconstituted as above, the reconstituted solution in the vial contains 5 mg alglucosidase alfa per ml. The reconstituted volume allows accurate withdrawal of 10.0 ml (equal to 50 mg) from each vial. This should then be further diluted as follows: Slowly withdraw the reconstituted solution from each vial until the volume for the patient's dose is obtained. The recommended final concentration of alglucosidase in the infusion bags ranges from 0.5 mg/ml to 4 mg/ml. Remove airspace within the infusion bag. Also remove an equal volume of 0.9% sodium chloride, that will be replaced with reconstituted Myozyme. Slowly inject the reconstituted Myozyme directly into the 0.9% sodium chloride solution. Gently invert or massage the infusion bag to mix the diluted solution. Do not shake or excessively agitate the infusion bag.
The final infusion solution should be administered as close to preparation time as possible.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in